Cargando…

PEGylated Domain I of Beta-2-Glycoprotein I Inhibits Thrombosis in a Chronic Mouse Model of the Antiphospholipid Syndrome

Antiphospholipid syndrome (APS) is an autoimmune disorder in which autoantibodies cause clinical effects of vascular thrombosis and pregnancy morbidity. The only evidence-based treatments are anticoagulant medications such as warfarin and heparin. These medications have a number of disadvantages, no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Willis, Rohan, McDonnell, Thomas C. R., Pericleous, Charis, Gonzalez, Emilio B., Schleh, Alvaro, Romay-Penabad, Zurina, Giles, Ian P., Rahman, Anisur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035797/ https://www.ncbi.nlm.nih.gov/pubmed/35479096 http://dx.doi.org/10.3389/fimmu.2022.842923

Ejemplares similares

PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome
por: McDonnell, Thomas C. R., et al.
Publicado: (2018)

Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I
por: McDonnell, Thomas, et al.
Publicado: (2018)

Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with ‘seronegative’ antiphospholipid syndrome
por: Cousins, Laura, et al.
Publicado: (2015)

Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β(2)-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis
por: Pericleous, Charis, et al.
Publicado: (2015)

Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS
por: McDonnell, Thomas, et al.
Publicado: (2015)

Oxidation of β2-glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome
por: Raimondo, Maria Gabriella, et al.
Publicado: (2017)

The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS
por: McDonnell, Thomas, et al.
Publicado: (2020)

Measuring IgA Anti-β2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome
por: Pericleous, Charis, et al.
Publicado: (2016)

Domain I of β2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect enhanced by PEGylation
por: Albay, A, et al.
Publicado: (2019)

Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?
por: Pericleous, Charis, et al.
Publicado: (2020)

Antiphospholipid antibodies enhance rat neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38 MAPK
por: Bourke, Lauren T, et al.
Publicado: (2017)

Antiphospholipid antibody positivity in early systemic lupus erythematosus is associated with subsequent vascular events
por: Farina, Nicola, et al.
Publicado: (2022)

Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome
por: Ripoll, Vera M., et al.
Publicado: (2018)

Evaluating the conformation of recombinant domain I of β(2)-glycoprotein I and its interaction with human monoclonal antibodies
por: Pericleous, Charis, et al.
Publicado: (2011)

Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome
por: Artim-Esen, Bahar, et al.
Publicado: (2017)

Novel Assays of Thrombogenic Pathogenicity in the Antiphospholipid Syndrome Based on the Detection of Molecular Oxidative Modification of the Major Autoantigen β(2)-Glycoprotein I
por: Ioannou, Yiannis, et al.
Publicado: (2011)

Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays
por: Artim-Esen, Bahar, et al.
Publicado: (2015)

Posttranslational forms of beta 2-glycoprotein I in the pathogenesis of the antiphospholipid syndrome
por: El-Assaad, Fatima, et al.
Publicado: (2016)

The Significance of Anti-Beta-2-Glycoprotein I Antibodies in Antiphospholipid Syndrome
por: Brusch, Anna
Publicado: (2016)

PEGylated drugs in rheumatology—why develop them and do they work?
por: McDonnell, Thomas, et al.
Publicado: (2014)

Going viral in rheumatology: using social media to show that mechanistic research is relevant to patients with lupus and antiphospholipid syndrome
por: McDonnell, Thomas C R, et al.
Publicado: (2018)

Purified IgG from Patients with Obstetric but not IgG from Non-obstetric Antiphospholipid Syndrome Inhibit Trophoblast Invasion
por: Poulton, Katie, et al.
Publicado: (2015)

Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome
por: Arachchillage, Deepa J., et al.
Publicado: (2023)

A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli
por: Ioannou, Yiannis, et al.
Publicado: (2006)

Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis
por: Lambrianides, Anastasia, et al.
Publicado: (2011)

Antibodies to beta(2)-glycoprotein I, prothrombin and antithrombin III as markers of the antiphospholipid syndrome severity
por: Zabek, J, et al.
Publicado: (2001)

Specific domain V reduction of beta-2-glycoprotein I induces protein flexibility and alters pathogenic antibody binding
por: Buchholz, Ina, et al.
Publicado: (2021)

Immune Complexes of Beta-2-Glycoprotein I and IgA Antiphospholipid Antibodies Identify Patients With Elevated Risk of Thrombosis and Early Mortality After Heart Transplantation
por: Serrano, Manuel, et al.
Publicado: (2019)

The Weight of IgA Anti-β2glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome
por: Cabrera-Marante, Oscar, et al.
Publicado: (2020)

Antiphospholipid antibodies and thrombosis: pathogenesis of antiphospholipid syndrome
por: Koike, T
Publicado: (2003)

Antibodies to FXa and thrombin in patients with SLE differentially regulate C3 and C5 cleavage
por: McDonnell, Thomas, et al.
Publicado: (2022)

Simultaneous Occurrence of Deep Vein Thrombosis and Carotid Artery Thrombosis in Antiphospholipid Antibody Syndrome
por: Mahale, Rohan R., et al.
Publicado: (2017)

Beta‐2‐Glycoprotein‐I Deficiency Could Precipitate an Antiphospholipid Syndrome‐like Prothrombotic Situation in Patients With Coronavirus Disease 2019
por: Serrano, Manuel, et al.
Publicado: (2021)

Pathophysiology of the antiphospholipid antibody syndrome
por: Willis, Rohan, et al.
Publicado: (2011)

Influence of anticardiolipin and anti‐β2 glycoprotein I antibody cutoff values on antiphospholipid syndrome classification
por: Vanoverschelde, Laura, et al.
Publicado: (2019)

Isolated IgA Anti-β2 Glycoprotein I Antibodies in Patients with Clinical Criteria for Antiphospholipid Syndrome
por: Ruiz-García, Raquel, et al.
Publicado: (2014)

16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends
por: Cohen, Hannah, et al.
Publicado: (2020)

IgG Autoantibodies against β(2)-Glycoprotein I Complexed with a Lipid Ligand Derived from Oxidized Low-Density Lipoprotein are Associated with Arterial Thrombosis in Antiphospholipid Syndrome
por: Lopez, Daniel, et al.
Publicado: (2003)

COVID-19, Antiphospholipid Syndrome and Thrombosis
por: Yasri, Sora, et al.
Publicado: (2020)

Eculizumab for refractory thrombosis in antiphospholipid syndrome
por: Hussain, Habiba, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r1h3futmehrjpedl7ep14bfehg